5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Available preclinical and phase 2 clinical data suggest that the addition of cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR), to chemotherapy might improve outcome in patients with advanced non-small-cell lung cancer (NSCLC). We aimed to assess whether the addition of cetuximab to chemotherapy improved progression-free survival in patients with recurrent or progressive NSCLC after platinum-based therapy.

          Related collections

          Author and article information

          Journal
          Lancet Oncol.
          The Lancet. Oncology
          1474-5488
          1470-2045
          Dec 2013
          : 14
          : 13
          Affiliations
          [1 ] Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA. Electronic address: Edward.Kim@carolinashealthcare.org.
          Article
          S1470-2045(13)70473-X
          10.1016/S1470-2045(13)70473-X
          24231627
          b81a457e-7785-4f5c-bedb-8cb2483c0dac
          Copyright © 2013 Elsevier Ltd. All rights reserved.
          History

          Comments

          Comment on this article